- Home
- DCTH vs REAL Comparison
DCTH vs REAL Comparison
Compare DCTH & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- REAL
- Stock Information
- Founded
- DCTH 1988
- REAL 2011
- Country
- DCTH United States
- REAL United States
- Employees
- DCTH N/A
- REAL N/A
- Industry
- DCTH Medical/Dental Instruments
- REAL Other Specialty Stores
- Sector
- DCTH Health Care
- REAL Consumer Discretionary
- Exchange
- DCTH Nasdaq
- REAL Nasdaq
- Market Cap
- DCTH 305.2M
- REAL 295.1M
- IPO Year
- DCTH N/A
- REAL 2019
- Fundamental
- Price
- DCTH $9.39
- REAL $3.99
- Analyst Decision
- DCTH Strong Buy
- REAL Buy
- Analyst Count
- DCTH 4
- REAL 7
- Target Price
- DCTH $21.50
- REAL $3.89
- AVG Volume (30 Days)
- DCTH 445.4K
- REAL 2.6M
- Earning Date
- DCTH 11-08-2024
- REAL 11-04-2024
- Dividend Yield
- DCTH N/A
- REAL N/A
- EPS Growth
- DCTH N/A
- REAL N/A
- EPS
- DCTH N/A
- REAL N/A
- Revenue
- DCTH $22,644,000.00
- REAL $579,862,000.00
- Revenue This Year
- DCTH $1,562.76
- REAL $10.55
- Revenue Next Year
- DCTH $117.72
- REAL $8.32
- P/E Ratio
- DCTH N/A
- REAL N/A
- Revenue Growth
- DCTH 945.91
- REAL 2.52
- 52 Week Low
- DCTH $2.38
- REAL $1.52
- 52 Week High
- DCTH $12.88
- REAL $4.64
- Technical
- Relative Strength Index (RSI)
- DCTH 40.91
- REAL 70.42
- Support Level
- DCTH $10.11
- REAL $3.63
- Resistance Level
- DCTH $12.88
- REAL $4.27
- Average True Range (ATR)
- DCTH 0.66
- REAL 0.25
- MACD
- DCTH -0.23
- REAL 0.08
- Stochastic Oscillator
- DCTH 12.75
- REAL 80.82
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the us, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 34% of net merchandise value, which excludes returns, cancellations, and first-party sales.